Clinical Study

Nrg-Gy006-A Randomized Phase II Trial Of Radiation Therapy And Cisplatin Alone Or In Combination With Intravenous Triapine In Women With Newly Diagnosed Bulky Stage Ib2, Stage II, IIIb, Or Iva Cancer Of The Uterine Cervix Or Stage II-Iva Vaginal

Posted Date: Jun 10, 2019

  • Investigator: Thomas Herzog
  • Specialties: Cancer, Oncology, Ovarian Cancer
  • Type of Study: Drug

To evaluate the efficacy of the experimental regimen of triapine (3AP), cisplatin, and radiation to increase progression-free survival relative to the standard / control regimen of cisplatin and radiation in women with uterine cervix and vaginal cancer.

Criteria:

To Be Eligible: Must Have New, Untreated Squamous, Adenocarcinoma, Or Adenosquamous Carcinoma Of The Uterine, Cervix Or Vagina, Life Expenceny Greater Than 20 Weeks, 18 Years Of Age Or Older, Non-Pregnant, No Current Or Prior Invasive Malignancy Within 3 Years,

Keywords:

Ovarian Cancer, Uterine Cancer

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.